FDA clears Perspectum's liver cancer decision tool

2021 01 28 23 20 2628 2021 01 28 Perspectum 20210128233120

The U.S. Food and Drug Administration (FDA) has cleared image analysis software developer Perspectum's Hepatica surgical decision-support tool for liver cancer.

Hepatica is a precision oncology decision-support tool for liver cancer. Image courtesy of Perspectum.Hepatica is a precision oncology decision-support tool for liver cancer. Image courtesy of Perspectum.

Surgery is a key liver cancer treatment option, and accurate presurgical staging is crucial, according to Perspectum. Hepatica uses quantitative, multiparametric MRI data to produce a liver health assessment that allows clinicians to make more informed decisions before surgery and thus improve postsurgery outcomes, the company said.

Page 1 of 605
Next Page